Spyre Therapeutics, Inc. Form SCHEDULE 13D/A — Oct 9, 2026
Fairmount Funds Management LLC and affiliated reporting persons filed Amendment No. 8 to their Schedule 13D on Spyre Therapeutics, disclosing entry into a lock-up agreement tied to the company's underwritten public offering that closed October 7, 2026. The filing states the number of beneficially owned shares has not changed since Amendment No. 7: the Fairmount entities hold 9,354,200 shares (9.19%), while Peter Evan Harwin and Tomas Kiselak hold 10,185,961 shares (9.99%), including common stock, Series A Preferred conversion shares, and option shares.
Key figures
- Shares Outstanding
- 0
- Lockup days
- 60
- Option shares
- 228646
- Common shares owned
- 812076
- Percent harwin kiselak
- 9.99%
- Series a preferred shares
- 227504
- Excluded conversion shares
- 4741640
- Percent fairmount entities
- 9.19%
- Shares issuable on conversion
- 9100160
- Aggregate shares harwin kiselak
- 10185961
- Aggregate shares fairmount entities
- 9354200
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.